Max Healthcare shares surged nearly 3% after Axis Capital initiated coverage with a BUY rating with a target price of Rs 1,315.
As per Axis Capital, Max Healthcare operates over 2,900 beds and dominates in oncology. The company plans to expand by adding 3,000 beds over the next three years through brownfield projects. Strong operational performance has fueled significant EBITDA growth and improved margins.
Max Healthcare is poised for sustained profitability and growth. Axis forecasts a 30% revenue growth and 31% EBITDA growth in FY25E, with continued positive momentum into FY26E (23% revenue and 24% EBITDA growth).
Max Healthcare shares opened at ₹1,132.00, reaching a high of ₹1,169.50 and a low of ₹1,126.20. The stock’s 52-week high also stands at ₹1,169.50, while the 52-week low is ₹630.90.
As of 11:49 am, Max Healthcare shares were trading 2.63% higher at Rs 1,161.95 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
